RT Journal Article
SR Electronic
T1 The ongoing COVID-19 epidemic in Minas Gerais, Brazil: insights from epidemiological data and SARS-CoV-2 whole genome sequencing
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.05.05.20091611
DO 10.1101/2020.05.05.20091611
A1 Xavier, Joilson
A1 Giovanetti, Marta
A1 Adelino, Talita
A1 Fonseca, Vagner
A1 da Costa, Alana Vitor Barbosa
A1 Ribeiro, Adriana Aparecida
A1 Felicio, Katlin Nascimento
A1 Duarte, Clara Guerra
A1 Silva, Marcos Vinicius Ferreira
A1 Salgado, Álvaro
A1 Lima, Mauricio Teixeira
A1 Jesus, Ronaldo de
A1 Fabri, Allison
A1 Zoboli, Cristiane Franco Soares
A1 Santos, Thales Gutemberg Souza
A1 Iani, Felipe
A1 de Filippis, Ana Maria Bispo
A1 de Siqueira, Marilda Agudo Mendonça Teixeira
A1 de Abreu, André Luiz
A1 de Azevedo, Vasco
A1 Ramalho, Dario Brock
A1 de Albuquerque, Carlos F. Campelo
A1 de Oliveira, Tulio
A1 Holmes, Edward C.
A1 Lourenço, José
A1 Alcantara, Luiz Carlos Junior
A1 Oliveira, Marluce Aparecida Assunção
YR 2020
UL http://medrxiv.org/content/early/2020/05/11/2020.05.05.20091611.abstract
AB The recent emergence of a previously unknown coronavirus (SARS-CoV-2), first confirmed in the city of Wuhan in China in December 2019, has caused serious public health and economic issues due to its rapid dissemination worldwide. Although 61,888 confirmed cases had been reported in Brazil by 28 April 2020, little was known about the SARS-CoV-2 epidemic in the country. To better understand the recent epidemic in the second most populous state in southeast Brazil (Minas Gerais, MG), we looked at existing epidemiological data from 3 states and sequenced 40 complete genomes from MG cases using Nanopore. We found evidence of multiple independent introductions from outside MG, both from genome analyses and the overly dispersed distribution of reported cases and deaths. Epidemiological estimates of the reproductive number using different data sources and theoretical assumptions all suggest a reduction in transmission potential since the first reported case, but potential for sustained transmission in the near future. The estimated date of introduction in Brazil was consistent with epidemiological data from the first case of a returning-traveler from Lombardy, Italy. These findings highlight the unique reality of MG’s epidemic and reinforce the need for real-time and continued genomic surveillance strategies as a way of understanding and therefore preparing against the epidemic spread of emerging viral pathogens.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the Pan American World Health Organization (PAHO) (VPGDI-003-FIO-19-2-2-30). MG is supported by Fundação de Amparo à Pesquisa do Estado do Rio de Janeiro (FAPERJ). V.F. and T.d.O. are supported by the South African Medical Research Council (MRC-RFA-UFSP-01-2013/UKZN HIVEPI) and the NIH H3AbioNet network, which is an initiative of the Human Health and Heredity in Africa Consortium (H3Africa). E.C.H. is supported by an Australian Research Council Australian Laureate Fellowship (FL170100022). J.L. is supported by a lectureship from the Department of Zoology, University of Oxford. J.X. and F.I is supported by the Coordenação de Aperfeiçoamento de Pessoal de Nível Superior - Brasil (CAPES) - Finance Code 001. F.I. is also supported by Fundação de Amparo à Pesquisa do Estado de Minas Gerais (FAPEMIG). A.S. has a scholarship from ZIKA-Announcement MCTIC/FNDCT-CNPq/MEC - CAPES/MS-Decit /No. 14/2016 - Prevention and Fight against Zika Virus. M.T.L. is supported by Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPQ). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesSARS-CoV-2 genome sequences generated in this study have been deposited in the GISAID platform (https://www.gisaid.org/), accession numbers IDs EPI_ISL_429664 to EPI_ISL_429703.